Spots Global Cancer Trial Database for malignant ascites
Every month we try and update this database with for malignant ascites cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases | NCT05477927 | Malignant Perit... Malignant Ascit... Serous Cavity M... | Dual-targeting ... | 18 Years - 65 Years | Sichuan University | |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02122185 | Brenner Tumor Malignant Ascit... Malignant Pleur... Ovarian Clear C... Ovarian Endomet... Ovarian Mixed E... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Ovaria... Stage IV Primar... | metformin hydro... placebo Chemotherapy | 18 Years - | University of Chicago | |
| AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites | NCT00396591 | Ovarian Neoplas... | Aflibercept (zi... | 18 Years - | Sanofi | |
| A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites | NCT03736122 | Malignant Pleur... Malignant Ascit... | BSG-001 | 21 Years - | BioSyngen Pte Ltd | |
| A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites | NCT02530398 | Digestive Syste... Malignant Ascit... | Cinobufacini In... | 18 Years - 80 Years | Dongfang Hospital Beijing University of Chinese Medicine | |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum | NCT00005860 | Cancer | floxuridine leucovorin calc... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites | NCT01065246 | Malignant Ascit... | catumaxomab | 18 Years - | Neovii Biotech | |
| CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers | NCT00822809 | Cancer Neoplasms Carcinoma Malignant Ascit... | Catumaxomab Prednisolone | 18 Years - | Neovii Biotech | |
| Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers | NCT01200121 | Malignant Ascit... Gastrointestina... | Bevacizumab Placebo | 18 Years - | AIO-Studien-gGmbH | |
| Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites | NCT01065246 | Malignant Ascit... | catumaxomab | 18 Years - | Neovii Biotech | |
| A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer | NCT06200376 | Malignant Ascit... | T3011 | 18 Years - 75 Years | West China Hospital | |
| Symptomatic Ascites Drainage With a Patient-controlled Vascular Catheter. | NCT02724683 | Malignant Ascit... | Ascites drainag... Interview. Quality of life... Quality of proc... Nutritional sta... | 18 Years - | Gdynia Oncology Center | |
| A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites | NCT03736122 | Malignant Pleur... Malignant Ascit... | BSG-001 | 21 Years - | BioSyngen Pte Ltd | |
| A Study of M701 (EpCAM and CD3) in Malignant Ascites | NCT04501744 | Malignant Ascit... Cancer | Cohort 1 of M70... Cohort 2 of M70... Cohort 3 of M70... Cohort 4 of M70... Cohort 5 of M70... Cohort 6 of M70... Cohort 7 of M70... | 18 Years - | Wuhan YZY Biopharma Co., Ltd. | |
| ALFApump System Post Marketing Surveillance Registry | NCT01532427 | Liver Cirrhosis Refractory Asci... Malignant Ascit... | - | Sequana Medical N.V. | ||
| SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) | NCT00002960 | Fallopian Tube ... Metastatic Canc... Ovarian Cancer Primary Periton... | recombinant ade... | 18 Years - 120 Years | Merck Sharp & Dohme LLC | |
| ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment | NCT00005645 | Fallopian Tube ... Metastatic Canc... Ovarian Cancer Primary Periton... | ILX-295501 | 18 Years - 120 Years | Sanofi | |
| Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group | NCT00836654 | EpCam Positive ... Malignant Ascit... | Catumaxomab (Re... paracentesis | 18 Years - | Neovii Biotech | |
| Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics | NCT04032600 | Malignant Ascit... Ovarian Cancer Hemodynamic Ins... | Paracentesis | 18 Years - | Charite University, Berlin, Germany | |
| Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody | NCT06266091 | Malignant Ascit... | M701 paracentesis | 18 Years - 75 Years | Wuhan YZY Biopharma Co., Ltd. | |
| Octreotide in Treating Patients With Cancer-Related Malignant Ascites | NCT00182754 | Metastatic Canc... Unspecified Adu... | octreotide acet... placebo | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Study of M701 (EpCAM and CD3) in Malignant Ascites | NCT04501744 | Malignant Ascit... Cancer | Cohort 1 of M70... Cohort 2 of M70... Cohort 3 of M70... Cohort 4 of M70... Cohort 5 of M70... Cohort 6 of M70... Cohort 7 of M70... | 18 Years - | Wuhan YZY Biopharma Co., Ltd. | |
| Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT | NCT02638051 | Peritoneal Neop... Ascites Yang Deficiency Yin Deficiency | Modulated Elect... TCM Herbal Deco... IPCI (CDDP+5FU) | 18 Years - 75 Years | Galenic Research Institute Ltd | |
| EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer | NCT00028782 | Advanced Malign... Localized Malig... Malignant Ascit... Primary Periton... Recurrent Malig... | etanidazole therapeutic con... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody | NCT06432296 | Malignant Ascit... | M701 paracentesis | 18 Years - 75 Years | Wuhan YZY Biopharma Co., Ltd. | |
| A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites | NCT02530398 | Digestive Syste... Malignant Ascit... | Cinobufacini In... | 18 Years - 80 Years | Dongfang Hospital Beijing University of Chinese Medicine | |
| Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs | NCT04985357 | Stage III Breas... Stage IV Breast... Stage III Lung ... Stage IV Lung C... AML Multiple Myelom... Carcinoma Carcinoma, Panc... Carcinoma of Lu... Carcinoma, Non-... Carcinoma Breas... Carcinoma Prost... Carcinoma, Hepa... Carcinoma, Rena... Carcinoma, Neur... Carcinoma, Smal... Carcinoma, Ovar... Carcinoma Bladd... Carcinoma of Es... Carcinoma Cervi... Carcinoma, Thym... Carcinoma, Duct... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of Un... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Malignant Pleur... Malignant Ascit... Mesothelioma Cholangiocarcin... | 18 Years - | Travera Inc | ||
| A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites | NCT03736122 | Malignant Pleur... Malignant Ascit... | BSG-001 | 21 Years - | BioSyngen Pte Ltd | |
| Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion | NCT01854866 | Malignant Pleur... Malignant Ascit... | Drug-packaging ... | 18 Years - 70 Years | Huazhong University of Science and Technology | |
| The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant Ascites | NCT02779608 | Stomach Neoplas... Peritoneal Meta... | intraperitoneal... oral S-1 | 20 Years - 75 Years | Fudan University | |
| Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites | NCT00326885 | Malignant Ascit... | catumaxomab | 18 Years - | Neovii Biotech | |
| Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer | NCT06016179 | Malignant Pleur... Malignant Ascit... | Tocilizumab | 18 Years - 89 Years | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | |
| Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites | NCT05745233 | Malignant Ascit... | Nivolumab Pembrolizumab | 20 Years - | China Medical University Hospital | |
| A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites | NCT06415500 | Gynecologic Can... | NK042 | 18 Years - 70 Years | Anhui Provincial Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
